US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
US6858615B2
(en)
|
2002-02-19 |
2005-02-22 |
Parion Sciences, Inc. |
Phenyl guanidine sodium channel blockers
|
EP1664006A2
(en)
|
2003-09-06 |
2006-06-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
CA2545719A1
(en)
*
|
2003-11-14 |
2005-06-02 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
LT2489659T
(lt)
*
|
2004-06-24 |
2018-03-26 |
Vertex Pharmaceuticals Incorporated |
Atp rišančios kasetės transporterių moduliatoriai
|
EP1912983B1
(en)
|
2005-08-11 |
2011-06-08 |
Vertex Pharmaceuticals, Inc. |
Modulators of cystic fibrosis transmembrane conductance regulator
|
HUE032640T2
(en)
*
|
2005-11-08 |
2017-10-30 |
Vertex Pharma |
Heterocyclic modulator of ATP-binding cassette transcripts
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
RS60205B1
(sr)
|
2005-12-28 |
2020-06-30 |
Vertex Pharma |
Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
|
US7691902B2
(en)
*
|
2005-12-28 |
2010-04-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
HUE055205T2
(hu)
*
|
2006-04-07 |
2021-11-29 |
Vertex Pharma |
ATP-kötõ kazetta transzporterek modulátorainak elõállítása
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2652072A1
(en)
*
|
2006-05-12 |
2007-11-22 |
Vertex Pharmaceuticals Incorporated |
Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8563573B2
(en)
*
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
US8969386B2
(en)
|
2007-05-09 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
ES2578735T3
(es)
|
2007-08-24 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística
|
US8551534B2
(en)
|
2007-10-10 |
2013-10-08 |
Parion Sciences, Inc. |
Inhaled hypertonic saline delivered by a heated nasal cannula
|
US8507524B2
(en)
|
2007-11-16 |
2013-08-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette-transporters
|
US8507534B2
(en)
|
2007-12-07 |
2013-08-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
BRPI0820681A2
(pt)
*
|
2007-12-07 |
2019-09-24 |
Vertex Pharma |
formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
|
CN101910134B
(zh)
|
2007-12-07 |
2014-03-19 |
沃泰克斯药物股份有限公司 |
环烷基甲酰氨基-吡啶苯甲酸类的生产方法
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
CN103382201B
(zh)
|
2008-02-28 |
2016-12-28 |
沃泰克斯药物股份有限公司 |
作为cftr调节剂的杂芳基衍生物
|
US8227615B2
(en)
|
2008-03-31 |
2012-07-24 |
Vertex Pharmaceutical Incorporated |
Pyridyl derivatives as CFTR modulators
|
US20100256184A1
(en)
*
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
MX2011003249A
(es)
|
2008-09-29 |
2011-05-19 |
Vertex Pharma |
Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
|
AR074060A1
(es)
*
|
2008-10-23 |
2010-12-22 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
|
LT2821400T
(lt)
*
|
2009-03-20 |
2018-02-12 |
Vertex Pharmaceuticals Incorporated |
Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorių gamybos būdas
|
WO2011050325A1
(en)
*
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
JP2013523833A
(ja)
†
|
2010-04-07 |
2013-06-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与
|
AR081069A1
(es)
|
2010-04-07 |
2012-06-06 |
Vertex Pharma |
Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico
|
CA2796642A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
EP2560650A1
(en)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
CA2797118C
(en)
|
2010-04-22 |
2021-03-30 |
Vertex Pharmaceuticals Incorporated |
Process of producing cycloalkylcarboxamido-indole compounds
|
NZ603386A
(en)
*
|
2010-05-20 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
PL3235812T3
(pl)
|
2011-05-18 |
2020-04-30 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterowane pochodne iwakaftoru
|
CA2838529C
(en)
|
2011-06-07 |
2020-03-24 |
Parion Sciences, Inc. |
Methods of treatment
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
EP2776427B1
(en)
|
2011-11-08 |
2017-02-01 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
CN109966264A
(zh)
|
2012-02-27 |
2019-07-05 |
沃泰克斯药物股份有限公司 |
药物组合物及其施用
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
KR102109223B1
(ko)
|
2012-05-29 |
2020-05-11 |
패리온 사이언스 인코퍼레이티드 |
안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드
|
EP2872122A1
(en)
|
2012-07-16 |
2015-05-20 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
WO2014078842A1
(en)
|
2012-11-19 |
2014-05-22 |
Concert Pharmaceuticals, Inc. |
Deuterated cftr potentiators
|
CA2896686A1
(en)
|
2012-12-17 |
2014-06-26 |
Parion Sciences, Inc. |
3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
|
RU2018138195A
(ru)
|
2012-12-17 |
2018-12-18 |
Пэрион Сайенсиз, Инк. |
Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
|
PE20151054A1
(es)
|
2012-12-17 |
2015-08-07 |
Parion Sciences Inc |
Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
|
JP6545148B2
(ja)
|
2013-03-13 |
2019-07-17 |
フラットリー ディスカバリー ラブ,エルエルシー |
ピリダジノン化合物及び嚢胞性線維症の治療のための方法
|
WO2015073231A1
(en)
|
2013-11-12 |
2015-05-21 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
|
US9102633B2
(en)
|
2013-12-13 |
2015-08-11 |
Parion Sciences, Inc. |
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
|
CN103787968B
(zh)
*
|
2014-02-27 |
2016-04-13 |
上海湖发化学技术有限公司 |
化合物的制备方法
|
KR102447581B1
(ko)
|
2014-04-15 |
2022-09-28 |
버텍스 파마슈티칼스 인코포레이티드 |
낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
|
PL3203840T3
(pl)
|
2014-10-06 |
2021-01-11 |
Vertex Pharmaceuticals Incorporated |
Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
|
KR20170063954A
(ko)
*
|
2014-10-07 |
2017-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
|
SI3221692T1
(sl)
|
2014-11-18 |
2021-11-30 |
Vertex Pharmaceuticals Inc. |
Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
|
GB201504878D0
(en)
|
2015-03-23 |
2015-05-06 |
Algipharma As |
Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
|
MA42954A
(fr)
|
2015-09-25 |
2018-08-01 |
Vertex Pharmaceuticals Europe Ltd |
Potentialisateurs cftr deutérés
|
GB201517639D0
(en)
|
2015-10-06 |
2015-11-18 |
Algipharma As |
Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
|
CN106187887B
(zh)
*
|
2016-07-01 |
2018-08-14 |
上海工程技术大学 |
4-羟基喹啉-3-甲酸的制备方法
|
WO2018064632A1
(en)
|
2016-09-30 |
2018-04-05 |
Vertex Pharmaceuticals Incorporated |
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
WO2018107100A1
(en)
|
2016-12-09 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
BR112019025801A2
(pt)
|
2017-06-08 |
2020-07-07 |
Vertex Pharmaceuticals Incorporated |
métodos de tratamento para fibrose cística
|
WO2019010092A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
|
AU2018304168B2
(en)
|
2017-07-17 |
2023-05-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
CA3069225A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
WO2019028228A1
(en)
|
2017-08-02 |
2019-02-07 |
Vertex Pharmaceuticals Incorporated |
PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
|
CN110770231B
(zh)
*
|
2017-10-18 |
2022-11-22 |
江苏恒瑞医药股份有限公司 |
一种酪氨酸激酶抑制剂及其中间体的制备方法
|
WO2019079760A1
(en)
|
2017-10-19 |
2019-04-25 |
Vertex Pharmaceuticals Incorporated |
CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
|
SG11202004264VA
(en)
|
2017-12-01 |
2020-06-29 |
Vertex Pharma |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
US20210228489A1
(en)
|
2017-12-04 |
2021-07-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
AU2018380426B2
(en)
|
2017-12-08 |
2023-05-18 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
PT3752510T
(pt)
|
2018-02-15 |
2023-03-15 |
Vertex Pharma |
Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los
|
WO2019195739A1
(en)
|
2018-04-05 |
2019-10-10 |
Alexander Russell Abela |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP3774825A1
(en)
|
2018-04-13 |
2021-02-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
PT3880197T
(pt)
|
2018-11-14 |
2023-05-09 |
Vertex Pharma |
Métodos de tratamento para a fibrose quística
|
UY38630A
(es)
|
2019-04-03 |
2020-10-30 |
Vertex Pharma |
Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
WO2020226889A1
(en)
*
|
2019-05-07 |
2020-11-12 |
Wellstat Therapeutics Corporation |
Formulations of uridine triacetate in triacetin
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
EP4013759A1
(en)
|
2019-08-14 |
2022-06-22 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2021030552A1
(en)
|
2019-08-14 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of cftr modulators
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
TW202115092A
(zh)
|
2019-08-14 |
2021-04-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
WO2022194399A1
(en)
|
2020-07-13 |
2022-09-22 |
Idorsia Pharmaceuticals Ltd |
Macrocycles as cftr modulators
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
AU2021325923A1
(en)
|
2020-08-13 |
2023-04-06 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
EP4225763A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076629A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225748A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225446A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CA3197857A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225765A2
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076628A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CA3197173A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20230365587A1
(en)
|
2020-10-07 |
2023-11-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4304593A1
(en)
*
|
2021-03-09 |
2024-01-17 |
Laurus Labs Limited |
Oral film of cftr modulator(s)
|
TW202333699A
(zh)
|
2022-02-03 |
2023-09-01 |
美商維泰克斯製藥公司 |
囊腫纖維化之治療方法
|
WO2023154291A1
(en)
|
2022-02-08 |
2023-08-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2023196429A1
(en)
|
2022-04-06 |
2023-10-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2023224931A1
(en)
|
2022-05-16 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
EP4335434A1
(en)
|
2022-08-17 |
2024-03-13 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical compositions comprising ivacaftor
|
WO2024056798A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Macrocyclic cftr modulators
|
WO2024056791A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
|
WO2024056779A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
|